Precipio, Inc. Q4 FY2024 earnings call

• CEO Ilan Danieli noted achieving breakeven in Q4 with positive and adjusted EBITDA and positive cash flow, aiming to transition from defense mode to offense for long-term growth. • Encouraged listeners to check Andrew's testimony on the website, highlighting the business's impact on real people. • Addressed challenges in products division onboarding: regulatory changes requiring product modifications, equipment/lab process issues causing delays, and personnel challenges in customer labs. • Announced Steve Miller's return to lead products division growth, leveraging his experience in the diagnostic field. • Plans to enhance financial market visibility, including participation in industry and investor conferences, increasing analyst coverage, and targeted investor engagement initiatives.

Pathology division: In Q4, revenues exceeded the $1.3 million per month breakeven point. Target for 2025 is to grow organically to approximately $25 million run rate, contributing to positive cash flow and supporting product division development. Products division: Q4 revenues were $700,000 (same as Q3). Challenges in onboarding customers due to regulatory changes, equipment/lab process issues, and personnel challenges. Historically direct sales were the majority, but they're revitalizing distribution strategy. Ended Q4 with $700,000 revenue (~$2.8 million run rate) and aim to double that to $5.6 million by end of 2025.

• Pathology division target for 2025: Continue organic growth to reach approximately $25 million run rate. • Products division aim: Double the Q4 run rate ($2.8 million) to $5.6 million by end of 2025. • Need to adapt to challenges, anticipate solutions for revenue stability, and grow customer base for diversity to ensure stable growth.

• Regulatory changes: Require product modifications and cause delays in onboarding customers. • Equipment and lab process challenges: Lead to delays in customer onboarding. • Personnel issues: In customer labs result in revenue gaps.